| Preview | Issue Date | Title / Name | Author(s) |
| Jul-2019 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer | Davis, I. D.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenbuerg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S, G,; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; Begbie, Stephen | |
| Dec-2024 | Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting - Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial | Grimison, P.; Mersiades, A.; Kirby, A.; Morton, R.L.; Walsh, A.; Lee, Y.; Simes, R.J.; Stockler, M.R.; Tognela, A.; Olver, I.; Haber, P.; Abdi, E.; Della-Fiorentina, S.; Aghmesheh, M.; Fox, P.; Briscoe, Karen; Sanmugarajah, J.; Marx, G.; Kichenadasse, G.; Wheeler, H.; Chan, M.; Shannon, J.; Gedye, C.; Begbie, Stephen; Briscoe, Karen; Begbie, Stephen | |
| Feb-2026 | Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304) | Inderjeeth, A-J.; Martin, A.J.; Zielinski, R.R.; Begbie, S.; Cheung, L.; Chowdhury, S.; Frydenberg, M.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.; McCaffrey, J.; McDermott, R.S.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.R.; Pook, D.W.; Reaume, M.N.; Sandhu, S.; Tan, A.; Tan, T.H.; Thomson, A.H.; Vera-Badillo, F.; Williams, S.G.; Thomas, H.; Yip, S.; Zhang, A.Y.; Chi, K.N.; Stockler, M.R.; Sweeney, C.J.; Davis, I.D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.; Begbie, Stephen D. | |
| Apr-2023 | Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial | Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Cheung, L.; Chi, K. N.; Chowdhury, S.; Frydenberg, M.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen | |
